Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

1 trials in Phase 3/4

Results Transparency

86%

6 of 7 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 2

6(60.0%)

Phase 1

3(30.0%)

Phase 3

1(10.0%)

10Total

Phase 2(6)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT05126758Phase 3Active Not Recruiting

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Role: lead

NCT04428476Phase 2Active Not Recruiting

Open-label Extension of the HOPE-2 Trial

Role: lead

NCT03406780Phase 2Completed

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Role: lead

NCT04623671Phase 2Completed

Intravenous Infusion of CAP-1002 in Patients With COVID-19

Role: lead

NCT02485938Phase 2Completed

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

Role: lead

NCT06304064Phase 2Completed

Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

Role: lead

NCT01458405Phase 1Terminated

Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration

Role: lead

NCT04338347Unknown

CAP-1002 in Severe COVID-19 Disease

Role: lead

NCT02359227Phase 2Completed

Safety Study of Cenderitide in Stable Chronic Heart Failure

Role: lead

NCT02603614Phase 1Completed

Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment

Role: lead

NCT03680365Completed

Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families

Role: collaborator

NCT02293603Phase 1Unknown

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

Role: lead

All 12 trials loaded